ACE PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
ACE PHARMA
Largest movements
- Stocks and contracts -€5,884
down €5,884 (-5.6%), from €104,719 to €98,835
- Receivables within one year +€5,029
up €5,029 (+8.8%), from €57,315 to €62,344
of which Trade receivables: +€9,240
- Cash +€4,856
up €4,856 (+5.6%), from €87,028 to €91,883
mainly Stocks and contracts (+€5,884) and Trade debts (+€4,376)
- Tangible fixed assets +€3,620
up €3,620 (+11.7%), from €30,816 to €34,436
of which Assets under construction and advance payments: +€5,985
- Profit (loss) carried forward +€10,492
up €10,492 (+9.2%), from €114,582 to €125,074
- Reserves -€8,655
down €8,655 (-9.3%), from €92,973 to €84,317
- Trade debts +€4,376
up €4,376 (+7.3%), from €59,656 to €64,032
- Gross operating margin +€27,036
up €27,036 (+117.6%), from €22,999 to €50,035
- Staff costs +€21,466
up €21,466 (+335.0%), from €6,408 to €27,874
- Other operating charges +€7,734
up €7,734 (+135.1%), from €5,724 to €13,458
- Taxes -€868
down €868 (-53.2%), from €1,631 to €763
- Financial charges +€528
up €528 (+35.5%), from €1,489 to €2,018
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €281,777 | €289,661 | +€7,885 | +2.8% |
| Fixed assets | 21/28 | €30,816 | €34,436 | +€3,620 | +11.7% |
| Tangible fixed assets | 22/27 | €30,816 | €34,436 | +€3,620 | +11.7% |
| Land and buildings | 22 | €25,977 | €23,477 | -€2,500 | -9.6% |
| Plant, machinery and equipment | 23 | €2,299 | €3,588 | +€1,289 | +56.0% |
| Furniture and vehicles | 24 | €2,540 | €1,387 | -€1,153 | -45.4% |
| Assets under construction and advance payments | 27 | - | €5,985 | +€5,985 | |
| Current assets | 29/58 | €250,961 | €255,225 | +€4,265 | +1.7% |
| Stocks and contracts in progress | 3 | €104,719 | €98,835 | -€5,884 | -5.6% |
| Stocks | 30/36 | €104,719 | €98,835 | -€5,884 | -5.6% |
| Amounts receivable within one year | 40/41 | €57,315 | €62,344 | +€5,029 | +8.8% |
| Trade receivables | 40 | €48,618 | €57,858 | +€9,240 | +19.0% |
| Other amounts receivable | 41 | €8,697 | €4,486 | -€4,211 | -48.4% |
| Cash at bank and in hand | 54/58 | €87,028 | €91,883 | +€4,856 | +5.6% |
| Deferred charges and accrued income | 490/1 | €1,899 | €2,163 | +€265 | +13.9% |
| Total equity and liabilities | 10/49 | €281,777 | €289,661 | +€7,885 | +2.8% |
| Equity | 10/15 | €219,955 | €221,792 | +€1,837 | +0.8% |
| Contributions | 10/11 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €92,973 | €84,317 | -€8,655 | -9.3% |
| Distributable reserves | 133 | €92,973 | €84,317 | -€8,655 | -9.3% |
| Profit (loss) carried forward | 14 | €114,582 | €125,074 | +€10,492 | +9.2% |
| Amounts payable | 17/49 | €61,821 | €67,870 | +€6,048 | +9.8% |
| Amounts payable within one year | 42/48 | €61,821 | €67,870 | +€6,048 | +9.8% |
| Trade debts | 44 | €59,656 | €64,032 | +€4,376 | +7.3% |
| Suppliers | 440/4 | €59,656 | €64,032 | +€4,376 | +7.3% |
| Taxes, remuneration and social security | 45 | €2,048 | €3,720 | +€1,672 | +81.7% |
| Taxes | 450/3 | €1,631 | €755 | -€876 | -53.7% |
| Remuneration and social security | 454/9 | €417 | €2,965 | +€2,548 | +611.4% |
| Other amounts payable | 47/48 | €118 | €118 | = | 0.0% |
| Remuneration, social security and pensions | 62 | €6,408 | €27,874 | +€21,466 | +335.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €4,312 | €4,360 | +€48 | +1.1% |
| Other operating charges | 640/8 | €5,724 | €13,458 | +€7,734 | +135.1% |
| Gross operating margin | 9900 | €22,999 | €50,035 | +€27,036 | +117.6% |
| Operating profit (loss) | 9901 | €6,556 | €4,343 | -€2,213 | -33.8% |
| Financial income | 75/76B | €553 | €274 | -€280 | -50.5% |
| Recurring financial income | 75 | €553 | €274 | -€280 | -50.5% |
| Financial charges | 65/66B | €1,489 | €2,018 | +€528 | +35.5% |
| Recurring financial charges | 65 | €1,489 | €2,018 | +€528 | +35.5% |
| Profit (loss) for the period before taxes | 9903 | €5,620 | €2,599 | -€3,021 | -53.7% |
| Income taxes | 67/77 | €1,631 | €763 | -€868 | -53.2% |
| Profit (loss) for the period | 9904 | €3,989 | €1,837 | -€2,153 | -54.0% |
| Profit (loss) for the period to be appropriated | 9905 | €3,989 | €1,837 | -€2,153 | -54.0% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 1 October 2026 via checked.be.